Skip to main content

Table 1 Number of subjects by study and dose.

From: Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder

 

Placebo

Fesoterodine 4 mg

Fesoterodine 8 mg

Fesoterodine 12 mg

Total

Phase II

     

   Cole, 2004 [7]

183

186

172

186

727

   Nitti et al, 2006 [8]

43

44

47

39

173

Phase III

     

   Chapple et al, 2007 [3]

277

263

276

0

816

   Nitti et al, 2007 [2]

265

266

267

0

798

Total

768

759

762

225

2514

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us